Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.12)
# 501
Out of 5,090 analysts
498
Total ratings
48.45%
Success rate
14.02%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines | Maintains: Buy | $258 → $340 | $191.83 | +77.24% | 29 | Dec 5, 2025 | |
| BHVN Biohaven | Downgrades: Neutral | $30 → $11 | $9.61 | +14.46% | 16 | Dec 3, 2025 | |
| DARE Daré Bioscience | Reiterates: Buy | $12 | $1.78 | +574.16% | 18 | Dec 2, 2025 | |
| PCRX Pacira BioSciences | Assumes: Buy | $38 | $23.97 | +58.53% | 3 | Nov 17, 2025 | |
| TBPH Theravance Biopharma | Maintains: Buy | $15 → $20 | $18.68 | +7.07% | 16 | Nov 11, 2025 | |
| NERV Minerva Neurosciences | Maintains: Neutral | $5 → $4 | $3.70 | +8.11% | 15 | Nov 6, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $57 → $45 | $22.05 | +104.13% | 27 | Oct 31, 2025 | |
| ARGX argenx SE | Maintains: Buy | $774 → $915 | $916.31 | -0.14% | 41 | Oct 31, 2025 | |
| CABA Cabaletta Bio | Reiterates: Buy | $16 | $2.60 | +516.57% | 27 | Oct 10, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Buy | $80 | $87.54 | -8.61% | 35 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1 | $2.08 | -51.92% | 18 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $20 | $21.18 | -5.55% | 21 | Sep 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $29.30 | +57.02% | 25 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $34 | $28.74 | +18.30% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $22.94 | +52.57% | 23 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $9.59 | +45.92% | 18 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $3.23 | +117.05% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $20 | $6.80 | +194.33% | 28 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $93.70 | +25.93% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $47.47 | +70.63% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $44.69 | +18.59% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.23 | +469.11% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $32.49 | +4.66% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $31.14 | -38.99% | 4 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.30 | +684.31% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.75 | +47,996.19% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.61 | +521.12% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $185.45 | -1.86% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $7.86 | +138.70% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $40.71 | -55.78% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $28.41 | -71.84% | 7 | Jun 11, 2019 |
Praxis Precision Medicines
Dec 5, 2025
Maintains: Buy
Price Target: $258 → $340
Current: $191.83
Upside: +77.24%
Biohaven
Dec 3, 2025
Downgrades: Neutral
Price Target: $30 → $11
Current: $9.61
Upside: +14.46%
Daré Bioscience
Dec 2, 2025
Reiterates: Buy
Price Target: $12
Current: $1.78
Upside: +574.16%
Pacira BioSciences
Nov 17, 2025
Assumes: Buy
Price Target: $38
Current: $23.97
Upside: +58.53%
Theravance Biopharma
Nov 11, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $18.68
Upside: +7.07%
Minerva Neurosciences
Nov 6, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $3.70
Upside: +8.11%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $57 → $45
Current: $22.05
Upside: +104.13%
argenx SE
Oct 31, 2025
Maintains: Buy
Price Target: $774 → $915
Current: $916.31
Upside: -0.14%
Cabaletta Bio
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $2.60
Upside: +516.57%
Protagonist Therapeutics
Oct 8, 2025
Reiterates: Buy
Price Target: $80
Current: $87.54
Upside: -8.61%
Sep 30, 2025
Reiterates: Neutral
Price Target: $1
Current: $2.08
Upside: -51.92%
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $21.18
Upside: -5.55%
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $29.30
Upside: +57.02%
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $34
Current: $28.74
Upside: +18.30%
Sep 4, 2025
Reiterates: Buy
Price Target: $35
Current: $22.94
Upside: +52.57%
Sep 3, 2025
Reiterates: Buy
Price Target: $14
Current: $9.59
Upside: +45.92%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.23
Upside: +117.05%
Aug 6, 2025
Maintains: Buy
Price Target: $27 → $20
Current: $6.80
Upside: +194.33%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $93.70
Upside: +25.93%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $47.47
Upside: +70.63%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $44.69
Upside: +18.59%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.23
Upside: +469.11%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $32.49
Upside: +4.66%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $31.14
Upside: -38.99%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $2.30
Upside: +684.31%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.75
Upside: +47,996.19%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.61
Upside: +521.12%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $185.45
Upside: -1.86%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $7.86
Upside: +138.70%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $40.71
Upside: -55.78%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $28.41
Upside: -71.84%